Abstract
This review summarizes the emerging roles of NHERF1/EBP50 adaptor protein in tumorigenesis. NHERF1/EBP50 (Na+/H+ exchanger regulating factor 1; ezrin-radixin-moesin (ERM) binding phosphoprotein of 50 kDa) is a PDZ domain-containing protein with physiological localization at the plasma membrane. We discuss in this review the functions of NHERF1/EBP50 as a linker between membrane proteins and the cytoskeleton network, as well as its involvement in different types of cancer, such as breast and liver cancers. Recent evidence obtained from our laboratory and from other groups shows that NHERF1/EBP50 is an important player in cancer progression. It appears that, depending on its subcellular distribution, NHERF1/EBP50 may behave either as a tumor suppressor, when it is localized at the plasma membrane, or as an oncogenic protein, when it is shifted to the cytoplasm. We provide here an overview of the mechanisms by which this adaptor protein controls cell transformation, and propose a model suggesting a dual role of NHERF1/EBP50 in cancer.
Keywords: NHERF1/EBP50, tumorigenesis, membrane proteins, cytoskeleton, liver cancers, cancer progression, oncogenic protein
Current Molecular Medicine
Title: Roles of NHERF1/EBP50 in Cancer
Volume: 8 Issue: 6
Author(s): Maria-Magdalena Georgescu, Fabiana C. Morales, Jennifer R. Molina and Yuho Hayashi
Affiliation:
Keywords: NHERF1/EBP50, tumorigenesis, membrane proteins, cytoskeleton, liver cancers, cancer progression, oncogenic protein
Abstract: This review summarizes the emerging roles of NHERF1/EBP50 adaptor protein in tumorigenesis. NHERF1/EBP50 (Na+/H+ exchanger regulating factor 1; ezrin-radixin-moesin (ERM) binding phosphoprotein of 50 kDa) is a PDZ domain-containing protein with physiological localization at the plasma membrane. We discuss in this review the functions of NHERF1/EBP50 as a linker between membrane proteins and the cytoskeleton network, as well as its involvement in different types of cancer, such as breast and liver cancers. Recent evidence obtained from our laboratory and from other groups shows that NHERF1/EBP50 is an important player in cancer progression. It appears that, depending on its subcellular distribution, NHERF1/EBP50 may behave either as a tumor suppressor, when it is localized at the plasma membrane, or as an oncogenic protein, when it is shifted to the cytoplasm. We provide here an overview of the mechanisms by which this adaptor protein controls cell transformation, and propose a model suggesting a dual role of NHERF1/EBP50 in cancer.
Export Options
About this article
Cite this article as:
Georgescu Maria-Magdalena, Morales C. Fabiana, Molina R. Jennifer and Hayashi Yuho, Roles of NHERF1/EBP50 in Cancer, Current Molecular Medicine 2008; 8 (6) . https://dx.doi.org/10.2174/156652408785748031
DOI https://dx.doi.org/10.2174/156652408785748031 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science The Bcl-2 Family as a Rational Target for the Treatment of B-Cell Chronic Lymphocytic Leukaemia
Current Medicinal Chemistry Zebrafish as a Model for the Study of the Phase II Cytosolic Sulfotransferases
Current Drug Metabolism Cytosine Methyltransferases as Tumor Markers
Current Genomics Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Synthesis and Studies of Anticancer and Antimicrobial Activity of New Phenylurenyl Chalcone Derivatives
Letters in Drug Design & Discovery Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Hepatitis B Virus X Protein Modulates Chemokine CCL15 Upregulation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Resistance in Cancer: A Target for Drug Discovery
Current Medicinal Chemistry - Anti-Cancer Agents Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy Microarray-Based Gene Expression Analysis of Hepatocellular Carcinoma
Current Genomics Preparation and Characterization of Silymarin Synchronized and Sustained Release Dropping Pill
Current Drug Delivery Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Antiviral Treatment of HCV Carriers with Persistently Normal ALT Levels
Mini-Reviews in Medicinal Chemistry Cytochrome P450 Gene Polymorphism and Cancer
Current Drug Metabolism Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Gamma-Oryzanol – A Multi-Purpose Steryl Ferulate
Current Nutrition & Food Science The Chemistry of Bioactive Diterpenes
Current Organic Chemistry Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design